Sightline Wealth Advisors’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $418K | Sell |
12,407
-387
| -3% | -$13.1K | 0.2% | 60 |
|
|
2025
Q1 | $407K | Sell |
12,794
-2,690
| -17% | -$85.5K | 0.21% | 55 |
|
|
2024
Q4 | $601K | Sell |
15,484
-827
| -5% | -$32.1K | 0.32% | 44 |
|
|
2024
Q3 | $734K | Sell |
16,311
-150
| -0.9% | -$6.75K | 0.4% | 41 |
|
|
2024
Q2 | $687K | Buy |
16,461
+950
| +6% | +$39.7K | 0.43% | 39 |
|
|
2024
Q1 | $706K | Sell |
15,511
-450
| -3% | -$20.5K | 0.47% | 35 |
|
|
2023
Q4 | $738K | Sell |
15,961
-2,113
| -12% | -$97.7K | 0.56% | 35 |
|
|
2023
Q3 | $735K | Buy |
18,074
+16
| +0.1% | +$651 | 0.69% | 34 |
|
|
2023
Q2 | $890K | Hold |
18,058
| – | – | 0.88% | 26 |
|
|
2023
Q1 | $890K | Sell |
18,058
-275
| -2% | -$13.6K | 0.91% | 24 |
|
|
2022
Q4 | $928K | Buy |
18,333
+4,728
| +35% | +$239K | 1% | 24 |
|
|
2022
Q3 | $685K | Buy |
13,605
+3,364
| +33% | +$169K | 0.8% | 20 |
|
|
2022
Q2 | $501K | Buy |
10,241
+5,247
| +105% | +$257K | 0.49% | 30 |
|
|
2022
Q1 | $300K | Buy |
4,994
+1,273
| +34% | +$76.5K | 0.25% | 44 |
|
|
2021
Q4 | $291K | Buy |
+3,721
| New | +$291K | 0.26% | 39 |
|